Finance

Beta
Lists
688513:SHA
Chengdu Easton Biopharmaceuticals Co Ltd
CN¥45.04
-2.85%
(-1.32) 1D
Jun 11, 11:29:27 AM GMT+8  ·   CNY
All symbols
SymbolPriceChange% Change
Generating top insights for 688513...
Open
CN¥46.13
High
CN¥46.32
Low
CN¥45.01
Mkt. cap
8.04B
Avg. vol.
1.93M
Volume
468.20K
Dividend
1.09%
Quarterly dividend
CN¥0.12
Ex-dividend date
Jun 2, 2026
P/E ratio
28.53
52-wk high
CN¥80.48
52-wk low
CN¥37.50
EPS
CN¥1.58
No. of employees
1K
Open
CN¥46.13
High
CN¥46.32
Low
CN¥45.01
Mkt. cap
8.04B
Avg. vol.
1.93M
Volume
468.20K
Dividend
1.09%
Quarterly dividend
CN¥0.12
Ex-dividend date
Jun 2, 2026
P/E ratio
28.53
52-wk high
CN¥80.48
52-wk low
CN¥37.50
EPS
CN¥1.58
No. of employees
1K
News stories
From sources across the web
About Chengdu Easton Biopharmaceuticals Co Ltd
CEO-
Employees1.48K
FoundedJun 1, 2009
Headquarters-
SectorPharmaceutical industry
Previous reportsAll values in CNY
Loading Previous Earnings...
Income statement
Revenue
Net income
All values in CNY
Jun 2025
Sep 2025
Dec 2025
Mar 2026
Revenue
348.81M
364.69M
312.26M
326.26M
Cost of goods sold
96.84M
87.18M
88.47M
73.62M
Cost of revenue
96.84M
87.18M
88.47M
73.62M
Research and development expenses
67.25M
54.95M
79.44M
72.66M
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
119.91M
136.71M
128.80M
143.86M
Operating expense
199.62M
197.59M
214.09M
212.02M
Total operating expenses
296.46M
284.77M
302.56M
285.64M
Operating income
52.34M
79.91M
9.70M
40.62M
Other non operating income
-41.85K
-228.90K
230.85K
-519.09K
EBT including unusual items
87.32M
92.35M
57.56M
47.40M
EBT excluding unusual items
56.88M
79.77M
51.53M
41.48M
Income tax expense
11.34M
8.76M
4.15M
4.12M
Effective tax rate
12.99%
9.49%
7.21%
8.69%
Other operating expenses
11.95M
4.49M
8.00M
-4.46M
Net income
75.98M
83.59M
63.90M
50.83M
Net profit margin
21.78%
22.92%
20.46%
15.58%
Earnings per share
-
-
-
-
Interest and investment income
5.10M
733.65K
42.65M
1.95M
Interest expense
-554.90K
-615.69K
-622.07K
-575.93K
Net interest expenses
4.55M
117.96K
42.02M
1.38M
Depreciation and amortization charges
-
-
-
-
EBITDA
73.02M
100.25M
32.44M
63.37M
Gain or loss from assets sale
-
-
-29.35K
-
AI content may include mistakes. Learn more

Research

AI content may include mistakes. Learn more